Two Sigma Advisers LP Sells 67,600 Shares of Inogen, Inc. (NASDAQ:INGN)

Two Sigma Advisers LP reduced its stake in shares of Inogen, Inc. (NASDAQ:INGN - Free Report) by 78.3% in the 4th quarter, according to its most recent 13F filing with the Securities and Exchange Commission. The firm owned 18,700 shares of the medical technology company's stock after selling 67,600 shares during the quarter. Two Sigma Advisers LP owned about 0.08% of Inogen worth $171,000 at the end of the most recent reporting period.

A number of other institutional investors and hedge funds also recently modified their holdings of the stock. Ieq Capital LLC acquired a new stake in shares of Inogen during the fourth quarter worth about $94,000. Bank of New York Mellon Corp boosted its position in shares of Inogen by 23.5% during the fourth quarter. Bank of New York Mellon Corp now owns 126,461 shares of the medical technology company's stock worth $1,160,000 after buying an additional 24,082 shares during the period. AlphaQuest LLC acquired a new position in shares of Inogen during the fourth quarter worth about $43,000. Connor Clark & Lunn Investment Management Ltd. raised its position in Inogen by 42.5% in the 4th quarter. Connor Clark & Lunn Investment Management Ltd. now owns 248,822 shares of the medical technology company's stock valued at $2,282,000 after buying an additional 74,197 shares during the last quarter. Finally, Monaco Asset Management SAM raised its position in Inogen by 104.0% in the 4th quarter. Monaco Asset Management SAM now owns 76,500 shares of the medical technology company's stock valued at $702,000 after buying an additional 39,000 shares during the last quarter. 89.94% of the stock is owned by institutional investors.

Analyst Ratings Changes

Several equities analysts have recently weighed in on the stock. Needham & Company LLC raised shares of Inogen from a "hold" rating to a "moderate buy" rating and set a $12.00 price target for the company in a research note on Thursday, May 22nd. Stifel Nicolaus reduced their target price on shares of Inogen from $10.00 to $7.00 and set a "hold" rating for the company in a report on Thursday, May 8th. Finally, Wall Street Zen lowered Inogen from a "buy" rating to a "hold" rating in a report on Wednesday, February 26th.

Inogen Stock Performance

Shares of INGN stock traded up $0.05 during midday trading on Monday, hitting $6.64. 126,588 shares of the company were exchanged, compared to its average volume of 239,977. Inogen, Inc. has a 52 week low of $5.70 and a 52 week high of $13.33. The firm has a market capitalization of $178.53 million, a P/E ratio of -2.95 and a beta of 1.64. The firm's 50 day moving average price is $6.72 and its two-hundred day moving average price is $8.44.

Inogen (NASDAQ:INGN - Get Free Report) last issued its quarterly earnings data on Wednesday, May 7th. The medical technology company reported ($0.25) earnings per share (EPS) for the quarter, topping analysts' consensus estimates of ($0.52) by $0.27. Inogen had a negative return on equity of 27.38% and a negative net margin of 15.89%. The company had revenue of $82.28 million during the quarter, compared to analysts' expectations of $79.57 million. Analysts expect that Inogen, Inc. will post -1.73 EPS for the current year.

About Inogen

Inogen, Inc, a medical technology company, develops, manufactures, and markets portable oxygen concentrators to patients, physicians and other clinicians, and third-party payors in the United States and internationally. Its oxygen concentrators are used to deliver supplemental long-term oxygen therapy to patients suffering from chronic respiratory conditions.